CTLA4 and melanoma: ICIs have revolutionized the therapeutic scenario of melanoma patients, the current standard treatment in advanced stages being antibodies against programmed death-1 (PD-1) (i.e., pembrolizumab, nivolumab) and CTLA-4 (i.e., ipilimumab) [90].